Roman Fabbricatore

Federal cuts to insurance and cancer research could reduce access to therapies and stifle progress when incidence is rising across many common cancers.

Data from the QUILT-3.032 trial supported the Saudi approval of nogapendekin alfa plus BCG in adults with BCG-unresponsive NMIBC with carcinoma in situ.

Patients with BPDCN who did not achieve a complete or clinical complete response during treatment experienced a restoration of hematopoiesis.

No grade 3 or greater treatment-related adverse effects or long-term safety signals emerged with gemogenovatucel-T in this ovarian cancer group.

Any-grade AEs were comparable between cadonilimab and a PD-1 monoclonal antibody regimen in this population, and no difference in grade 3/4 AEs emerged.

Ash Tewari, MBBS, hopes that with institutional partner aid, in 10 years, 1 million men will undergo prostate cancer screening through mobile units.

The acceptance of the application is based on phase 3 MANEUVER study findings, in which pimicotinib improved responses vs placebo in this group.

In patients less likely to respond to neoadjuvant chemoradiation, postoperative adjuvant therapy may be a viable strategy in this ESCC group.

The phase 1 ARTISAN trial investigators plan to expand enrollment to patients with metastatic CRPC outside the US in the second half of 2026.

Patient demands for efficacious regimens without sacrificing quality of life are driving a greater emphasis on managing and mitigating AEs in oncology.

Consistent with FGFR2 inhibition, lirafugratinib was well-tolerated among patients with FGFR2-mutated cholangiocarcinoma in the ReFocus trial.

The safety profile of chemoradiotherapy with or without tislelizumab was acceptable among patients with gastric cancer or gastroesophageal junction cancer.

Patients with gastric cancer who were treated with a 3-drug antiemetic regimen had lower discontinuation rates following the first zolbetuximab dose.

No serious adverse effects were observed with CBM588 in patients at risk of colorectal adenoma recurrence.

Overall survival and progression-free survival benefits with the combinations were consistent among prespecified subgroups based on PD-L1 status.

Larger-scale and longer-term studies could elucidate the mechanisms underlying quality of life benefits associated with resistance exercise in this group.

Previously, the phase 2 EVANGELINE trial assessed treatment with (Z)-endoxifen in this patient group.

BI-1808 plus pembrolizumab was safe and well-tolerated among patients with recurrent ovarian cancer.

Preclinical data from the phase 2 SUMMIT trial presented at the 2025 ASH meeting support the submission for bezuclastinib in this patient group.

The overall safety profile of melphalan/HDS was comparable among relevant subgroups, with an absence of cumulative toxicity in successive treatment cycles.

Findings suggest a need for interventions to promote equitable use for underrepresented groups and promote PRO use in those with higher symptom burden.

Although findings did not show differences in eating restrictions 1 month following gastrectomy, the mobile intervention may help with symptom management.

The addition of zovegalisib to fulvestrant led to rapid declines in PIK3CA and ESR1 ctDNA in the HR-positive/HER2-negative advanced breast cancer group.

From KRAS inhibitors in metastatic CRC to radioligands and PET imaging agents in prostate cancer, dozens of oncologic approvals were reported in 2025.

Among 35 patients with ovarian cancer treated with an antibody-based combination, the overall response rate was 23%, with a clinical benefit rate of 31%.

A total of 33% of patients with advanced prostate cancer receiving the combination therapy remained progression-free per PSA after 1 year of treatment.

Pooled analysis data from the phase 1 JSKN003-101 and phase 1/2 JSKN003-102 trials support the regulatory decision.

The tafasitamab-based regimen was previously approved by the FDA in June 2025 for patients with relapsed/refractory follicular lymphoma.

The γ-secretase inhibitor varegacestat conferred an 84% reduction in the risk of progression or death vs placebo among those with desmoid tumors.

Patients 70 years and older with newly diagnosed multiple myeloma experienced higher response rates and prolonged survival with Isa-Rd vs Rd alone.